

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**JW (Cayman) Therapeutics Co. Ltd**

**藥明巨諾（開曼）有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2126)**

## **NOTICE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of JW (Cayman) Therapeutics Co. Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board is scheduled to be held on Wednesday, March 29, 2023 for the purposes of, among other matters, (i) considering and approving the annual audited consolidated results of the Group for the year ended December 31, 2022 and its publication; (ii) recommendation of a final dividend, if any; and (iii) transacting any other business.

By order of the Board  
**JW (Cayman) Therapeutics Co. Ltd**  
藥明巨諾（開曼）有限公司\*  
**Yiping James Li**  
Chairman

Shanghai, PRC, March 17, 2023

*As at the date of this announcement, the Board comprises Dr. Yiping James Li as Chairman and executive Director, Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr. Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive Directors, and Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho, Dr. Debra Yu as independent non-executive Directors.*

\* For identification purpose only